ZHEJIANG MEDICINE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.53 CNY | +0.42% |
|
+2.47% | -11.18% |
| Apr. 25 | Zhejiang Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 2023 | Zhejiang Medicine Wins Nod to Trial Digestive Acid Drug | MT |
ETFs positioned on Zhejiang Medicine Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 31 M€ | +3.50% | - | |
| 0.00% | 34 M€ | +2.14% | - |
Zhejiang Medicine Co., Ltd. is a China-based company, principally engaged in the manufacture and distribution of drugs and nourishments. The Company mainly provides nourishments for animals and human, health care products, and chemicals and chemical raw materials, among others. The Company's products include synthetic vitamin E, natural vitamin E soft capsules, Beta carotene, vancomycin hydrochloride for injection and teicoplanin for injection, among others. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
9.53
CNY
Average target price
11
CNY
Spread / Average Target
+15.42%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -11.18% | 1.26B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 600216 Stock
- Funds and ETFs Zhejiang Medicine Co., Ltd.
